Outcomes of patients with active cancers and pre-existing cardiovascular diseases infected with SARS-CoV-2.

ABSTRACT:

Objective

To determine the impact of acute SARS-CoV-2 infection on patient with concomitant active cancer and CVD.

Methods

The researchers extracted and analyzed data from the National COVID Cohort Collaborative (N3C) database between January 1, 2020, and July 22, 2022. They included only patients with acute SARS-CoV-2 infection, defined as a positive test by PCR 21 days before and 5 days after the day of index hospitalization. Active cancers were defined as last cancer drug administered within 30 days of index admission. The "Cardioonc" group consisted of patients with CVD and active cancers. The cohort was divided into four groups: (1) CVD (-), (2) CVD ( +), (3) Cardioonc (-), and (4) Cardioonc ( +), where (-) or ( +) denotes acute SARS-CoV-2 infection status. The primary

SUBMITTER: Patel B 

PROVIDER: S-EPMC10557272 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature